GSK

GSK acquires full rights to globally develop, manufacture and commercialize mRNA vaccine candidates for influenza and COVID-19, including combinations CureVac to receive €400 million upfront and up to €1.05 billion additional in development, regulatory and sales milestone payments, as well as tiered royalties; replacing all previous financial considerations from the prior collaboration agreement GSK plc … Read more